Circulogene Theranostics Liquid Biopsy Research Accepted for Abstract Presentation at AACR Annual Meeting

Researchers to present clinical study data on next-generation sequencing for blood-drop liquid biopsy

BIRMINGHAM, Ala., February 17, 2016 (BUSINESS WIRE) –  Circulogene Theranostics announced today that a study conducted on next generation sequencing for liquid biopsies has been accepted for presentation at the upcoming American Association of Clinical Research (AACR) 2016 Annual Meeting in New Orleans.

The study, titled “Clinical validation of a next-generation sequencing assay specifically for blood-drop liquid biopsy,” will be presented on Tuesday, Apr 19, 2016, from 8:00 a.m. until 12:00 p.m. in Poster Section 22 in Convention Center Halls G-J by Circulogene Chief Scientific Officer Chen-Hsiung Yeh, Ph.D.

“It is an honor to be chosen to present our research at this prestigious cancer research gathering,” said Yeh. “Non-invasive liquid biopsies such as ours represent a significant advance over traditional surgical tumor biopsies, and our research aims to further validate the clinical efficacy of our unique methodology.”

The proof-of-principle study was coauthored by University of Alabama-Birmingham Department of Pathology Professor Upender Manne, Ph.D., M.S., who commented, “We’re looking forward to this important presentation, building on previous research to further demonstrate the potential advances in patient management and treatment provided by next generation liquid biopsy using only droplet volumes of blood.”

Circulogene is the first and only biotechnology company able to enrich circulating cell-free DNA from a single blood drop for patient-specific monitoring of cancer. The company currently provides testing for breast, colorectal, lung, gastric, gastrointestinal stromal (GIST), hematological, melanoma, ovarian, pancreatic and thyroid cancers. Circulogene is currently partnering with researchers across the country to conduct further clinical trials at leading biotechnology research universities.

The clinical study results will be presented in the Circulating Biomarkers 2 session under Clinical Research and published in the 2016 Proceedings of the AACR. Circulogene is Clinical Laboratory Improvement Amendments (CLIA) certified, and it plans to expand research initiatives to independently demonstrate greatly increased sensitivity and specificity compared to current methods. For more information, visit our website, connect with us on LinkedIn, email us at info@circulogene.com or call 855-614-7083. Clinicians interested in ordering the test may visit the Contact page on Circulogene’s website.

###

About Circulogene Theranostics

Headquartered in Birmingham, Ala., Circulogene Theranostics is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA liquid biopsies, Circulogene has developed the only droplet-volume, next-generation sequencing (NGS) method to provide full genomic load analysis, enabling more accurate data to help clinicians and their patients. For more information, visit www.circulogene.com or call 205-278-1600.  

Media Contact
Dan Snyders
Armada Medical Marketing
dan@armadamedical.com
303-623-1190 ext. 230

Company Contact
Scott Rezek
srezek@Circulogene.com
205-278-1607